$SKVI
SKINVISIBLE, INC. Stock $skvi

$skvi Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000166357723000137 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$5.000K	$5.000K	$279.3K
YoY Change	-91.66%	-98.02%	-57.9%
Cost Of Revenue		$0.00	$4.808K
YoY Change			45.7%
Gross Profit	$5.000K	$5.000K	$274.5K
YoY Change	-91.45%	-98.02%	-58.42%
Gross Profit Margin	100.0%	100.0%	98.28%
Selling, General & Admin	$128.3K	$118.0K	$494.2K
YoY Change	-3.87%	17.25%	8.82%
% of Gross Profit	2565.2%	2359.6%	180.04%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$4.640K	$4.740K	$18.74K
YoY Change	1.09%	0.85%	4.46%
% of Gross Profit	92.8%	94.8%	6.83%
Operating Expenses	$132.9K	$122.7K	$512.9K
YoY Change	-3.7%	16.53%	8.66%
Operating Profit	-$127.9K	-$117.7K	-$238.4K
YoY Change	60.8%	-179.78%	-226.77%
Interest Expense	$1.384M	-$282.9K	$1.163M
YoY Change	-611.04%	-11.55%	-184.85%
% of Operating Profit
Other Income/Expense, Net	$1.387M		$986.5K
YoY Change	927.67%		-21.76%
Pretax Income	-$1.515M	-$400.6K	-$1.225M
YoY Change	606.26%	142.22%	14.18%
Income Tax
% Of Pretax Income
Net Earnings	-$1.515M	-$400.6K	-$1.225M
YoY Change	606.26%	142.22%	14.18%
Net Earnings / Revenue	-30301.12%	-8011.6%	-438.56%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.33	-$0.09	-$0.27
COMMON SHARES
Basic Shares Outstanding	4.594M shares	4.540M shares	4.540M shares
Diluted Shares Outstanding	4.540M shares		4.540M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.14K	$81.38K	$81.38K
YoY Change	16.1%	23.23%	23.23%
Cash & Equivalents	$29.14K	$81.38K
Short-Term Investments
Other Short-Term Assets	$3.810K	$9.500K	$9.500K
YoY Change	-23.8%	16.85%	16.85%
Inventory
Prepaid Expenses
Receivables	$40.18K	$19.07K	$19.07K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$73.13K	$109.9K	$110.0K
YoY Change	108.17%	48.09%	48.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$132.7K	$136.8K	$136.8K
YoY Change	-10.6%	-10.59%	-10.6%
TOTAL ASSETS
Total Short-Term Assets	$73.13K	$109.9K	$110.0K
Total Long-Term Assets	$132.7K	$136.8K	$136.8K
Total Assets	$205.9K	$246.8K	$246.8K
YoY Change	12.13%	8.58%	8.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$126.1K	$1.202M	$1.202M
YoY Change	-86.66%
Accrued Expenses	$2.110M	$1.956M	$1.956M
YoY Change	32.32%	32.59%	32.59%
Deferred Revenue
YoY Change
Short-Term Debt	$433.6K	$433.6K	$433.6K
YoY Change	-5.92%	-5.92%	-5.92%
Long-Term Debt Due	$40.00K	$40.00K	$40.00K
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$2.726M	$3.645M	$3.645M
YoY Change	-11.11%	19.07%	19.07%
LONG-TERM LIABILITIES
Long-Term Debt	$5.635M	$3.242M	$3.242M
YoY Change	105.16%	25.59%	25.59%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$5.635M	$3.242M	$3.242M
YoY Change	105.16%	25.59%	25.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.726M	$3.645M	$3.645M
Total Long-Term Liabilities	$5.635M	$3.242M	$3.242M
Total Liabilities	$8.362M	$6.887M	$6.887M
YoY Change	43.82%	22.05%	22.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$38.51M	-$37.00M
YoY Change		3.42%
Common Stock	$4.540K	$4.540K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$8.156M	-$6.641M	-$6.641M
YoY Change
Total Liabilities & Shareholders Equity	$205.9K	$246.8K	$246.8K
YoY Change	12.13%	8.58%	8.57%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.515M	-$400.6K	-$1.225M
YoY Change	606.26%	142.22%	14.18%
Depreciation, Depletion And Amortization	$4.640K	$4.740K	$18.74K
YoY Change	1.09%	0.85%	4.46%
Cash From Operating Activities	-$51.72K	-$45.51K	$45.17K
YoY Change	26.32%	-129.59%	-87.94%
INVESTING ACTIVITIES
Capital Expenditures	$530.00	$520.00	$2.530K
YoY Change			-112.13%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$525.00	-$520.00	-$2.530K
YoY Change			-87.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	-$27.30K
YoY Change		-100.0%	-91.56%
NET CHANGE
Cash From Operating Activities	-$51.72K	-45.51K	$45.17K
Cash From Investing Activities	-$525.00	-520.0	-$2.530K
Cash From Financing Activities		0.000	-$27.30K
Net Change In Cash	-$52.24K	-46.03K	$15.34K
YoY Change		-373.66%	-49.12%
FREE CASH FLOW
Cash From Operating Activities	-$51.72K	-$45.51K	$45.17K
Capital Expenditures	$530.00	$520.00	$2.530K
Free Cash Flow	-$52.25K	-$46.03K	$42.64K
YoY Change	27.61%	-129.92%	-89.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001085277
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022	us-gaap	Payments For Loans PaymentsForLoans		usd
CY2022	us-gaap	Interest Paid InterestPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature		usd
CY2021	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature		usd
CY2022	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts		usd
CY2021	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts		usd
CY2022	SKVI	Common Stock Payable Conversion Of Debt Value CommonStockPayableConversionOfDebtValue		usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber		shares
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-25911
CY2022	dei	Entity Registrant Name EntityRegistrantName	Skinvisible, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0344219
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	6320 South Sandhill Road
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 10
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Las Vegas
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89120
CY2022	dei	City Area Code CityAreaCode	702
CY2022	dei	Local Phone Number LocalPhoneNumber	433.7154
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	551261	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4593843	shares
CY2022	dei	Auditor Name AuditorName	Gries & Associates, LLC
CY2022	dei	Auditor Location AuditorLocation	Denver, Colorado
CY2022	dei	Auditor Firm AuditorFirmId	6778
CY2022Q4	us-gaap	Cash Cash	81378	usd
CY2021Q4	us-gaap	Cash Cash	66037	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	19073	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	82	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9495	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8125	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	109946	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	74244	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	136847	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	153055	usd
CY2022Q4	us-gaap	Assets Assets	246793	usd
CY2021Q4	us-gaap	Assets Assets	227299	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1201937	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1039661	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1955820	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1475067	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	27299	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	433600	usd
CY2021Q4	us-gaap	Loans Payable LoansPayable	433600	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	40000	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	40000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	13629	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	45664	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3644986	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3061293	usd
CY2022Q4	SKVI	Debt Instrument Related Party Unamortized Discount Premium Net DebtInstrumentRelatedPartyUnamortizedDiscountPremiumNet	1228066	usd
CY2021Q4	SKVI	Debt Instrument Related Party Unamortized Discount Premium Net DebtInstrumentRelatedPartyUnamortizedDiscountPremiumNet	1837918	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	2992143	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	2382291	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	101808	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	152642	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	250267	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	199433	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6887396	usd
CY2021Q4	us-gaap	Liabilities Liabilities	5643017	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4539843	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4539843	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4539843	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4539843	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4540	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4540	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30352905	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30352905	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36998048	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35773161	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6640603	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5415716	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	246793	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	227299	usd
CY2022	us-gaap	Revenues Revenues	279296	usd
CY2021	us-gaap	Revenues Revenues	663426	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	4808	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	3300	usd
CY2022	us-gaap	Gross Profit GrossProfit	274488	usd
CY2021	us-gaap	Gross Profit GrossProfit	660126	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18738	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	17939	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	494182	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	454107	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	512920	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	472046	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-238432	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	188080	usd
CY2022	us-gaap	Interest Expense InterestExpense	1162869	usd
CY2021	us-gaap	Interest Expense InterestExpense	1213043	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	32035	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-157478	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	144379	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	109688	usd
CY2022	us-gaap	Other Expenses OtherExpenses	986455	usd
CY2021	us-gaap	Other Expenses OtherExpenses	1260833	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1224887	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1072753	usd
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.27
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.24
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4539843	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4539843	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4539843	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4539843	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-4454779	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	111816	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1072753	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-5415716	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1224887	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6640603	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1224887	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1072753	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18738	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	17939	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	660686	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	645686	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	144379	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	109688	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	32035	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-157478	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1370	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1625	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-18991	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7636	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	306655	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	174166	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-7616	usd
CY2022	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	480753	usd
CY2021	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	563382	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	45170	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	374605	usd
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	2530	usd
CY2021	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	20864	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2530	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20864	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	27299	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	25200	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	180000	usd
CY2021	us-gaap	Payments For Loans PaymentsForLoans	118400	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-27299	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-323600	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15341	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	30141	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66037	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35896	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81378	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66037	usd
CY2021	us-gaap	Interest Paid InterestPaid	12631	usd
CY2021	SKVI	Common Stock Payable Conversion Of Debt Value CommonStockPayableConversionOfDebtValue	59602	usd
CY2022Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	136847	usd
CY2022	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1998-03-06
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1224887	usd
	us-gaap	Net Income Loss NetIncomeLoss	-36998048	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zpcWx8LDM8ni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Use of estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"/>The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"> </p>
CY2022Q4	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	4572284	usd
CY2022	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	23609820	shares
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	27299	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	25200	usd
CY2022Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	0	usd
CY2021Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	27299	usd
CY2019Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2464480	usd
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	966203	usd
CY2019Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	617915	usd
CY2019Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	64423	usd
CY2019Q2	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Reported Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseReportedClaimsAmount	11942	usd
CY2019Q2	us-gaap	Advance Royalties AdvanceRoyalties	110245	usd
	us-gaap	Debt Instrument Description DebtInstrumentDescription	The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	148273	usd
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	153591	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	129535	usd
CY2019Q4	us-gaap	Taxes And Licenses TaxesAndLicenses	1000000	usd
CY2022	SKVI	Percent Payment Due To Avoid Termination PercentPaymentDueToAvoidTermination	0.50	pure
CY2022	SKVI	License Fee Agreement Terms LicenseFeeAgreementTerms	As partial consideration for the rights conveyed by Skinvisible under this Agreement, Licensee agrees to pay to Skinvisible a one-time, non-refundable, non-creditable license issue fee of one million USD dollars (USO $1,000,000) (''License Fee'').
	SKVI	License Revenues LicenseRevenues	1000000	usd
CY2022	SKVI	License Revenues2 LicenseRevenues2	250000	usd
CY2020Q2	us-gaap	Payments To Acquire Management Contract Rights PaymentsToAcquireManagementContractRights	100000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	37000000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	37000000.0	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	15700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7800000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3300000	usd
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	7800000	usd
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	3300000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	37000000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	15700000	usd
CY2022	SKVI	Schedule Of Option Summary ScheduleOfOptionSummary	<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfOptionSummary_zITZSFtYbGp3" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - 10. STOCK OPTIONS AND WARRANTS - Schedule of Option Summary (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: justify; padding-bottom: 1pt">Balance, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231_zMXcsAjYV7vc">30,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--ExcercisePriceOneMember_zclxG24BTqv9">1.51</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options granted and assumed</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231_zAJ5lpDUKtB5"><span style="-sec-ix-hidden: xdx2ixbrl0496">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zcLsGYubAzI3"><span style="-sec-ix-hidden: xdx2ixbrl0497">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zcHnC2D7iTi5">30,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--OptionExerciseMember_zSi9NrRm8YU8"><span style="-sec-ix-hidden: xdx2ixbrl0499">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options canceled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_zzD3spWj1PD5"><span style="-sec-ix-hidden: xdx2ixbrl0500">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--OptionCancelledWeightedAverageMember_zl0DnbuBHS04"><span style="-sec-ix-hidden: xdx2ixbrl0501">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Options exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z9dNwsXSnCy4"><span style="-sec-ix-hidden: xdx2ixbrl0502">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zENToWc58ue1"><span style="-sec-ix-hidden: xdx2ixbrl0503">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231_zms683xuYoa1"><span style="-sec-ix-hidden: xdx2ixbrl0504">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--ExcercisePriceTwoMember_zPQE9hejR7v8">1.51</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	30000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	30000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4539843	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4539843	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4539843	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4539843	shares

Files In Submission

Name	View Source	Status
skvi-20221231_cal.xml	Edgar Link	unprocessable
0001663577-23-000137-index-headers.html	Edgar Link	pending
0001663577-23-000137-index.html	Edgar Link	pending
0001663577-23-000137.txt	Edgar Link	pending
0001663577-23-000137-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
skvi-20221231.xsd	Edgar Link	pending
skvi10k123122.htm	Edgar Link	pending
skvi-20221231_def.xml	Edgar Link	unprocessable
skvi-20221231_lab.xml	Edgar Link	unprocessable
skvi-20221231_pre.xml	Edgar Link	unprocessable
skvi10k123122_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKVI
SKINVISIBLE, INC. Stock $skvi

2023 Q1 Form 10-K Financial Statement

#000166357723000137 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKVI SKINVISIBLE, INC. Stock $skvi

2023 Q1 Form 10-K Financial Statement

#000166357723000137 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKVI
SKINVISIBLE, INC. Stock $skvi